Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Jeon, Chanhoo ^a   Kim, Myong ^a   Kwak, Cheol ^a   Kim, Hyeon Hoe ^a   Ku, Ja Hyeon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN;

ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84885694720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076719     Document Type: Article

References (70)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Ambrosini G, Adida C, Altieri DC, (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
3. Margulis V, Lotan Y, Shariat SF, (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26: 59-65.
4. Pennati M, Folini M, Zaffaroni N, (2008) Targeting survivin in cancer therapy. Expert Opin Ther Targets 12: 463-476.
5. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM, (2007) Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60.
6. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, et al. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134.
7. Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, et al. (2003) Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 9: 1098-1104.
8. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, et al. (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65: 4881-4887.
9. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, et al. (2009) Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 182: 78-84.
10. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, et al. (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14: 85-90.
11. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, et al. (2010) Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 106: 710-715.
12. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, et al. (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101: 149-159.
13. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, et al. (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456-1466.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
15. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
16. Williamson PR, Smith CT, Hutton JL, Marson AG, (2002) Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21: 3337-3351.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
18. Duchateau L, Collette L, Sylvester R, Pignon JP, (2000) Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get! Biometrics. 56: 886-892.
19. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, et al. (2005) Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21: 119-125.
20. Hirooka T, Hamada C, Yoshimura I, (2009) A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis. Methods Inf Med 48: 104-112.
21. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
23. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM, (2003) Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 170: 230-234.
24. Wang H, Xi X, Kong X, Huang G, Ge G, (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 130: 487-490.
25. Wu Y, Wang G, Wei J, Wen X, (2005) Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Indian J Med Sci 59: 235-242.
26. Mowla SJ, Emadi Bayegi M, Ziaee SA, Nikpoor P, (2005) Evaluating expression and potential diagnostic and prognostic values of survivin in bladder tumors: a preliminary report. Urol J 2: 141-147.
27. López-Knowles E, Hernández S, Kogevinas M, Lloreta J, Amorós A, et al. (2006) EPICURO Study Investigators. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12: 6029-6036.
28. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y, (2007) Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 25: 468-475.
29. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, et al. (2007) Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 177: 1163-1168.
30. Schultz IJ, De Kok JB, Witjes JA, Babjuk M, Willems JL, et al. (2007) Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence. Anticancer Res 27: 1051-1058.
31. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, et al. (2007) Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 51: 416-422.
32. Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, et al. (2009) Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol J 6: 101-108.
33. Atlasi Y, Mowla SJ, Ziaee SA, (2009) Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev 32: 308-313.
34. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, et al. (2009) Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol 175: 1824-1830.
35. Yildirim U, Erdem H, Kayikci A, Sahin AF, Uzunlar AK, et al. (2010) Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density. J Int Med Res 38: 1689-1699.
36. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, et al. (2010) Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 57: 12-20.
37. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, et al. (2010) Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 183: 1744-1750.
38. Dong ZL, Lu ZP, Wang HZ, Zhang LY, Wang ZP, et al. (2011) Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy. Urol Int 87: 445-449.
39. Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, et al. (2012) Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. World J Urol 30: 785-794.
40. Jaiswal PK, Goel A, Mandhani A, Mittal RD, (2012) Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 39: 5615-5121.
41. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, et al. (2013) Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 107: 550-554.
42. Sun YW, Xuan Q, Shu QA, Wu SS, Chen H, et al. (2013) Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res 12: 1045-1053.
43. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, et al. (2002) Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 10: 134-138.
44. Weikert S, Christoph F, Schrader M, Krause H, Miller K, et al. (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116: 100-104.
45. Wang Y, Zhu Z, Zeng F, Wang L, Wu Y, et al. (2007) Expression and prognostic significance of survivin in the progression of bladder transitional cell cancer. J Huazhong Univ Sci Technolog Med Sci 27: 444-447.
46. Kitsukawa S, Aoyagi T, Noda K, Ito T, Yamamoto Y, et al. (2008) Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. Hinyokika Kiyo 54: 101-106.
47. Gonzalez S, Aubert S, Kerdraon O, Haddad O, Fantoni JC, et al. (2008) Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J Clin Pathol 129: 232-237.
48. Jang TJ, Lee KS, (2009) The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma Korean J Pathol. 43: 206-211.
49. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, et al. (2011) ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One 6: e27616.
50. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, et al. (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8: 128-136.
51. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, et al. (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109: 1106-1113.
52. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, et al. (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23: 3327-3331.
53. Ku JH, Kwak C, Lee HS, Park HK, Lee E, et al. (2004) Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171: 631-635.
54. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, et al. (2004) Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 50: 1425-1428.
55. Yin W, Chen N, Zhang Y, Zeng H, Chen X, et al. (2006) Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 19: 1487-1497.
56. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF, (2007) Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70: 482-486.
57. Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, et al. (2007) Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol 9: 731-736.
58. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, et al. (2009) Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining. Anticancer Res 29: 4163-4167.
59. Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, et al. (2009) Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 74: 1455-1460.
60. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, et al. (2012) Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 180: 1824-1834.
61. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, et al. (2013) Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 107: 550-554.
62. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, et al. (2009) Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 15: 7012-7019.
63. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, et al. (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-4414.
64. Stewart LA, Parmar MK, (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341: 418-422.
65. Altman DG, Lausen B, Sauerbrei W, Schumacher M, (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835.
66. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, et al. (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115: 575-585.
67. Li F, Ling X, (2006) Survivin study: an update of "what is the next wave"? J Cell Physiol 208: 476-486.
68. Li F, Yang J, Ramnath N, Javle MM, Tan D, (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114: 509-512.
69. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, et al. (1997) Language bias in randomised controlled trials published in English and German. Lancet 350: 326-329.
70. Hayes DF, Isaacs C, Stearns V, (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6: 375-392.